| Literature DB >> 22831177 |
Carsten Goessl1, Leonid Katz, William C Dougall, Paul J Kostenuik, Holly Brenza Zoog, Ada Braun, Roger Dansey, Rachel B Wagman.
Abstract
Denosumab is a fully human monoclonal antibody against RANK ligand (RANKL), an essential cytokine for the formation, function, and survival of osteoclasts. The role of excessive RANKL as a contributor to conditions characterized by bone loss or bone destruction has been well studied. With its novel mechanism of action, denosumab offers a significant advance in the treatment of postmenopausal osteoporosis; bone loss associated with hormone ablation therapy in women with breast cancer and men with prostate cancer; and the prevention of skeletal-related events in patients with bone metastases from solid tumors by offering clinical benefit to these patients in need.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22831177 DOI： 10.1111/j.1749-6632.2012.06674.x
Source DB: PubMed Journal: Ann N Y Acad Sci ISSN： 0077-8923 Impact factor: 5.691